









The Centre for Health Economics Research and Evaluation (CHERE) was 
established in 1991.  CHERE is a centre of excellence in health economics and 
health services research. It is a joint Centre of the Faculties of Business 
and Nursing, Midwifery and Health at the University of Technology, Sydney, in 
collaboration with Central Sydney Area Health Service. It was established as a 
UTS Centre in February, 2002. The Centre aims to contribute to the development 
and application of health economics and health services research through 
research, teaching and policy support. CHERE’s research program encompasses 
both the theory and application of health economics. The main theoretical 
research theme pursues valuing benefits, including understanding what 
individuals value from health and health care, how such values should be 
measured, and exploring the social values attached to these benefits. The 
applied research  focuses on economic and the appraisal of new programs or new 
ways of delivering and/or funding services. CHERE’s teaching includes 
introducing clinicians, health services managers, public health professionals 
and others to health economic principles. Training programs aim to develop 
practical skills in health economics and health services research. Policy 
support is provided at all levels of the health care system by undertaking 
commissioned projects, through the provision of formal and informal advice as 
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Background: There are several perceived benefits from introducing positron emission 
tomography (PET) scanning into the staging of non small lung cancer (NSCLC). 
However, its greatest primary benefit is the role it can potential perform in reducing the 
number of unnecessary diagnostic examinations and futile surgeries.  
 
Objectives: To evaluate the economic impact and cost effectiveness of PET scanning in 
the management of potentially operable NSCLC patients using a cost-utility model.  
 
 Methods: A literature review was conducted to find relevant studies and appropriate 
parameters to construct a decision model. Two strategies were compared. The first 
strategy was a conventional work up (CWU) consisting of an x-ray, a chest computer 
tomography (CT) scan and brochoscopy; the second strategy consisted of a CWU plus a 
whole body PET scan. These two strategies were applied to two sub-groups of NSCLC 
patients; those that had received a positive result on their CT scan and those that got a 
negative result on their CT scan. The cost-effectiveness of each strategy was dependent 
on a number of variables that were taken from a literature review. Costs were based on 
the Australian diagnostic related groups, a cost calculation for a chemotherapy course and 
values obtained from the literature. The life expectancy and utility scores were also taken 
from the literature and combined to create an incremental quality adjusted life year 
(QALY) value for PET for each of the patient groups.  
 
Results: The mean costs in CT negative and CT positive patients were lower in the CWU 
strategy, costing $A 20,427 and $A 23,578 per patient respectively compared to the PET 
strategy ($A 20,826 and $A 24,083 per patient respectively). The mean QALYs for both 
the CT positive and CT negative patients were higher in PET with 2.91 and 2.11 
respectively compared to the CWU of 2.88 and 2.09. The incremental cost effectiveness 
ratio (ICER) for the CT negative strategy was $A 14,581 and $A 52,039 for the CT 
positive strategy. 
 
Conclusion: The PET strategy in CT negative and CT positive patients appears to be cost 
effective, however, there is much uncertainty surrounding this base result, particularly in 






Lung cancer is the leading cause of cancer related deaths in the western world with non 
small lung cancer (NSCLC) accounting for around 75-80% of cases and small cell lung cancer 
(SCLC) accounting for the rest.
1 In Australia there are approximately 8,200 cases of lung 
cancer diagnosed every year.
2 Lung cancer was the fifth most common cancer reported in 
cancer registries in 1998, but it was the leading cause of death from cancer accounting for 
20.1% of cancer deaths. In the year 2000, lung cancer was responsible for 22.8% of male 
cancer deaths and 14.9% of female cancer deaths and 5.3% of total Australian deaths.
3 The 
correct and efficient diagnosis, staging and treatment of lung cancer is therefore essential and 
any small improvement in the handling on NSCLC could have significant effects in both 
decreasing costs to the Australian healthcare system and improving the length and quality of 
life of patients. 
Lung cancer usually arises in the bronchi in response to repetitive carcinogenic stimuli, 
inflammation and irritation. Disruption of the cell development occurs in the mucosal lining 
and progresses to elevate and erode the basel membrane. The tumour then spreads throughout 
the lung and will eventually metastasise to the lymph nodes and to other parts of the body.
4 
There are four main histological classifications of lung cancer. There are three that are closely 
related in their behaviour and management, these are squamous cell carcinomas, 
adenocarcinomas and large cell carcinomas and these are usually grouped as NSCLC: these 
will be the focus of this evaluation. In contrast SCLC has a distinct natural history and 
management and will not be assessed here.
5   
 
The accurate staging of NSCLC  
 
The management of NSCLC is directed by staging based on tumour size and location, 
nodal involvement, and the presence or absence of distant metastasis. The aim of staging 
NSCLC is to accurately identify the group of patients who will have the greatest survival 
benefit from either surgical resection or radical radiotherapy and chemotherapy.
 6 Currently, up 
to 50% of operations in early stage lung cancer are futile due to the presence of locally 
advanced tumours or distant metastasis.
7  Therefore there is a real need to improve the number 
of correctly staged NSCLC patients and in so doing reducing the number of futile operations 
that occur.
 
 Staging NSCLC at the time of diagnosis is done by the TNM classification system 
which then both guides management and predicts outcome. The various T, N and M factors are 
grouped in different stages (from 0 to IV) in which patients are ranked to produce a system 
                                                 
1Devaraj, A., G. J. Cook, et al. (2007). "PET/CT in non-small cell lung cancer staging-promises and problems." 
Clinical Radiology 62(2),  p. 97. 
2 http://www.cancer.org.au//aboutcancer/cancertypes/lungcancernonsmallcell.htm Lung Cancer Council. 3rd 
September 2007. 
3 Clinical Practice Guidelines for the Prevention, Diagnosis of Lung Cancer. National Health and Medical 
Research Council (2004), p. 3. 
4 Clinical practice guidelines, p. 3. 
5Clinical Practice Guidelines for the Prevention, Diagnosis of Lung Cancer. National Health and Medical 
Research Council (2004) , p. 3 
6Clinical Practice Guidelines for the Prevention, Diagnosis of Lung Cancer. National Health and Medical 
Research Council (2004), p. 53. 
7 National Institute of Health and Clinical Effectiveness, “The Diagnosis and treatment of Lung Cancer; Methods, Evidence 
and Guidance. National Collaboration Centre of Acute Care. 2005. 
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with a ‘high prognostic value.’
8 Although practice varies from centre to centre patients with 
stage IIIB and above are usually considered inappropriate for surgery. Some patients with IIIA 
may be treated with chemotherapy with a view of down staging the tumour before radiotherapy 
or surgery. Meanwhile, stage I and II patients are treated with either a lobectomy or 
pneumonectomy with some receiving adjuvant chemotherapy.
9 In this study, all surgery will be 
classed under the more general heading of a thoractomy.  
 
Figure 1: The Stage grouping (TNM subsets).  
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Currently, the investigation of patients suspected of having lung cancer is based on a set 
of ‘conventional’ diagnostic techniques. A chest x-ray is usually the initial first step for 
detecting the presence of a pulmonary lesion, which always warrants further examination as it 
raises the suspicion of lung cancer. Then a brochoscopy or a transthoracic needle biopsy are 
usually used to determine the exact nature of the pulmonary lesion as these procedures produce 
a sample of the lesion that can be analysed. 
10 Once lung cancer is detected it is then staged to 
ascertain the spread of the disease and to see if the cancer is treatable or palliative care is 
needed. 
  Traditionally, computer tomography (CT) has been the mainstay of non-invasive 
staging. There is, however, undoubtedly a variation in the performance of CT in its ability to 
accurately evaluate the individual TNM components. CT has a role in the basic T staging of 
NSCLC with respect to the size and the location of the tumour and the extent of invasion of 
chest wall because of its excellent anatomical description. However, given CT relies on 
morphological detail rather than histological characteristics its use in the N staging of NSCLC 
                                                 
8 Chiti, A., F. A. Schreiner, et al. (1999). "Nuclear medicine procedures in lung cancer." Eur J Nucl Med 26(5), p. 
536. 
9 Devaraj, A., G. J. Cook, et al. (2007). "PET/CT in non-small cell lung cancer staging-promises and problems." 
Clinical Radiology 62(2), p.99. 
10 Nguyen, V. H., S. Peloquin, et al. (2005). "Cost-effectiveness of positron emission tomography for the 
management of potentially operable non-small cell lung cancer in Quebec" Canadian Respiratory Journal 12(1), 
pp.19-20. 
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has been questioned.
11 Therefore CT assessment has been estimated to incorrectly over stage 
or under stage T and N status in 40% of cases. Therefore some form of surgical verification is 
needed to confirm the CT scan. The value of the mediastinoscopy as a further staging 
procedure is widely accepted mainly due to its high specificity in detecting nodal involvement. 
However, it does have limitations as it can not access all lymph nodes (reducing its sensitivity). 
Furthermore, it also carries a small mortality risk.
12 In the last 15 years positron emission 
tomography (PET) has promised to improve the staging in NSCLC. There is a large literature 
supporting PET as a useful tool in detecting distant metastasis and it is generally considered 




What is FDG-PET? 
 
PET is an imaging method that allows the metabolic rate of normal and disease tissue to 
be compared using radiotracers, which other medical imaging techniques are unable to do. 
Malignant tumours have a markedly accelerated metabolism, which can be visualised by 18F-
fluoro-2-dexy-D-glucose (FDG) due to a higher uptake of glucose in the tumour. Elevated 
uptake of FDG has been demonstrated in all lung cancer cell types and this radiotracer is used 
in most studies of lung cancer. The patient is administrated 350-500 megabecquerels (MBq) of 
FDG with the data being acquired after an uptake interval of between 30 to 60 minutes. Whole 
body imaging is used for screening and staging outside the limited primary field of view. False 
positive results are reported and account for the lower specificity of FDG-PET relative to its 
sensitivity. Reasons for false positives are mostly of an inflammatory nature. The high negative 
predictive value of PET in mediastinal staging allows patients with a negative scan to 
procedure to thoractomy without invasive mediastinal staging by mediastinoscopy. However it 
will only be through the correct combination of CT, mediastinoscopy and PET procedures that 
the most cost effective outcome to correctly stage NSCLC will be found.
14
 
Some of the potential benefits of PET identified by the Bradbury et al study
15 were to: 
 
a)  Increase the number of correct operations for N0/1 M0 patients and also to reduce 
the number of missed operations within this group.  
b)  Avoid the resource cost of futile operations for which it does not offer a potential 
cure. i.e N2/N3, M1 patients. 
c)  Avoid the mortality and morbidity of futile operations, especially the number of 
‘open and shut” cases where the patients are opened up but they are inoperable and 
are then referred to palliation. 
d)  Allow palliative care to be offered at an earlier stage for symptom control and more 
appropriate care to be given. 
e)  Reduce the number of other diagnostic tests to be given. 
                                                 
11 Devaraj, A., G. J. Cook, et al. (2007). "PET/CT in non-small cell lung cancer staging-promises and problems." 
Clinical Radiology 62(2), p. 99. 
12 Clinical Practice Guidelines for the Prevention, Diagnosis of Lung Cancer. National Health and Medical 
Research Council (2004) p.54. 
13 Nguyen, V. H., S. Peloquin, et al. (2005). "Cost-effectiveness of positron emission tomography for the 
management of potentially operable non-small cell lung cancer in Quebec" Canadian Respiratory Journal 12(1): 
p.20. 
 
14 Chiti, A., F. A. Schreiner, et al. (1999). "Nuclear medicine procedures in lung cancer." Eur J Nucl Med 26(5),  
pp. 544-545. 
15 Bradbury et al. Heakth Technology Board Scotland, Positron Emission Tomography (PET) Imaging in Cancer 
Management” October 2002. 
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They identified a set of potential costs of PET as: 
 
a)  The cost of setting up and running a PET scanner. 
b)  A change in the number of correct operations in N0/N1 M0 patients due to the 
specificity of PET and false positive results.  
c)  Additional costs of palliative care treatment to patients if given at an earlier stage. 




The literature was searched to identify any relevant cost effectiveness studies, reviews 
and randomised control trials (RCT’s) concerning the use of FDG-PET in the staging of lung 
cancer. The peer-reviewed databases that were searched were PubMed and Cochrane. The 
relevant studies which were identified in the literature had their references hand searched and 
assessed to ascertain if any relevant studies had been overlooked. The inclusion/exclusion 
criteria were as follows: 
 
Inclusion criteria     
 
•  Studies in English  
•  Studies published between 1990 and June 2007 
•  Studies using FDG as the radio-labelled tracer 
•  Cost effectiveness studies, cost utility studies or random control trials (RCTs) selected. 
 
Exclusion Criteria  
 
•  Studies not focused on NSCLC 
•  Studies not relevant to the topic  
 
There were 6 cost effectiveness studies and 3 cost utility studies identified, in addition 
to 3 RCT’s.. A summary of the studies are given in the Appendix.  
    
There were three cost utility studies that looked at the staging of PET with two of these 
being from the UK and one from Japan. The first UK Study was conducted by Bradbury et al 
for the Health Technology Board Scotland (HTBS)
16 and the other UK study was undertaken 
by the National Institute of Health and Clinical Effectiveness (NICE) in England and Wales.
17 
These studies are both very recent and they have built and improved upon previous studies to 
give two comprehensive models using the available NSCLC literature. Furthermore, their use 
of QALYs to take account of the differences in the patient morbidities found in the different 
stages and treatments of NSCLC sets them apart from the cost effectiveness studies. Therefore, 
the majority of the literature review will be based on these two studies. The third cost utility 
study by Hayashi et al was less explicit on the sources of their data especially those concerning 
the utilities used and so will only be briefly looked at below.  
                                                 
16 Bradbury et al. Health Technology Board Scotland, “Positron emission tomography (PET) imaging in cancer 
management” October 2002.  
17 National Institute of Health and Clinical Effectiveness, “The Diagnosis and treatment of Lung Cancer; Methods, 
Evidence and Guidance. National Collaboration Centre of Acute Care. 2005. 
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HTBS Study  
 
The HTBS study is based on a decision analysis with seven possible strategies 
analysed. They conducted their own meta-analysis to estimate the sensitivity and specificity of 
PET. The majority of parameters used in the model were taken from the Dietlein study.
18 The 
costs were estimated from a detailed costing of a Scottish PET facility. All patients had a 
definite diagnosis of NSCLC, were fit for surgery and had a conventional work up (CWU), 
which usually consists of a chest x–ray, brochoscopy and a CT scan. If the CT scan was 
positive then the patients had enlarge nodes and therefore a greater risk of mediastinal 
metastasis or distant metastasis, whereas these risk was reduced if the results were CT 
negative,  in other words the nodes were normal. It was assumed that the rate of metastasis was 
10% and could only be detected by PET.   
The results for the CT positive patients found that two strategies which noticeably 
outperformed the other strategies. These were Strategy 3 (mediastinoscopy all and no PET), 
which had the second best outcome. Strategy 7 (mediastinoscopy after positive PET) had the 
best outcome and had a higher number of QALYs compared to just giving a PET scan with no 
further staging procedures to everyone mainly because of the relatively poor detection of 
enlarged N2/3 patients compared to the 100% specificity of mediastinoscopy. The incremental 
cost effectiveness ratio (ICER) was extremely high with a value of £59,000 per QALY relative 
to the threshold implicitly used by NICE in the UK and therefore does not  seem to be cost 
effective at any current acceptable national healthcare threshold.  
The results for CT negative patients found that strategies 1, 3 and 7 dominated the other 
strategies. Strategy 1 (send all to surgery) was the third best outcome with Strategy 3 the 
second best and  Strategy 7 having the best incremental cost per QALY of £10,500. This 
suggests that using PET for CT negative patients is a cost effective strategy in this model.  
 
NICE Study  
 
The NICE study was also based and built upon the HTBS and Dietlein studies. They 
looked at two groups of patients who were expected to benefit most from PET. The first was 
those patients with normal sized lymph nodes (i.e. negative) on CT being considered for PET, 
they excluded positive patients because they felt that these patients would not benefit due to the 
high ICER recorded in the HTBS study. The second group were patients that were being 
considered for radical radiotherapy this consisted mainly of those patients with enlarged nodes 
(i.e positive) on CT.  
 
In the surgery model they considered three strategies. Under the first strategy patients 
went straight to thoractomy. In the second, the patients have a mediastinoscopy and then either 
receive radical radiotherapy (N2/3) or thoractomy (N0/1). In the third strategy patients have a 
PET scan and then receive either active supportive care (M1), thoractomy (N0/1, M0) or 
mediastinoscopy (N2/3, M0).They found that the mediastinoscopy strategy was dominated by 
the PET strategy. The PET strategy compared to the thoractomy strategy resulted in 22% fewer 
futile thoractomies, 1% fewer surgical deaths and a more appropriate selection of patients for 
radical radiotherapy. This resulted in an increase in life expectancy of 0.04 per patient and an 
                                                 
18 Dietlein, M., K. Weber, et al. (2000). "Cost-effectiveness of FDG-PET for the management of potentially 
operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results." Eur J Nucl 
Med 27(11): 1598-609 
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increase of 0.04 QALYs per patient. The estimated ICER of the PET strategy compared to the 
thoractomy strategy was £7,200 per QALY gained. 
 
In the radiotherapy model only two strategies were compared. The first was that all 
patients go straight to radiotherapy and the second was that all patients have a PET scan and 
then receive active supportive care (M1), thoractomy (N0/1) or radical radiotherapy (N2/3). 
Compared to the radiotherapy strategy the PET strategy had less futile radiotherapies and some 
patients benefiting from curative surgery. However, some patients missed radical 
radiotherapies and some had unnecessary surgery. Overall, the estimated incremental cost was 
£9,489 per QALY gained showing PET to be a cost effective strategy rather than sending 
patients straight to radiotherapy.  
 
Other International Studies 
 
There are three further cost effectiveness studies that show similar results to the HTBS 
and NICE studies that a mediastinoscopy after positive PET is the most cost effective strategy. 
All were based on decision analyses. Dietlein found that this strategy in CT negative patients 
had a cost per life years (LYs) gained of €143, and in CT positive patients a cost per LYG of 
€36,667.
19 Scott et al found like the HTBS report that this strategy was only cost effective in 
negative patients.
20 While Gambhir et al did not evaluate PET separately but found overall that 
using this strategy for both positive and negative patients resulted in savings of $1,154 per 
patient without a loss of life expectancy.
21 The Hayashi et al cost utility study also confirmed 
the mediastinoscopy after positive PET strategy more cost effective than just conventional 
imaging with an ICER of $US7,555 per QALY for patients with 20% mediastinal metastasis 
ranging up to $44,000 per QALY for patients with 80% mediasstinal metaststasis, they did not 
differentiate between CT positive and CT negative patients.  
The cost effectiveness study by Verboom
22 based on Dutch randomised control trial 
undertaken by Van Tinternern et al
23 compared a CWU with a CWU + PET strategy. The 
study showed that the additional use of PET in the staging of patients with NSCLC reduced 
unnecessary thoractomies by 20% when compared to CWU and saved costs. On the other 
hand, the economic evaluation conducted alongside Viney’s Australian randomised control 
trial suggested that only 0.22 thoractomies were avoided between the no PET and PET arms. 
However, this trial only recruited stage I and II candidates who have a low probability of 
mediastinal lymph node involvement or distant metastasis reducing the likelihood of a futile 
thoractomy and so in this case PET was found not to be cost effective.
24
Therefore, the literature suggests that PET is a cost effective study when used in 
conjunction with a mediastinoscopy after a positive result in CT negative patients compared to 
                                                 
19 Dietlein, M., K. Weber, et al. (2000). "Cost-effectiveness of FDG-PET for the management of potentially 
operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results." Eur J Nucl 
Med 27(11): 1598-609 
20 Scott, W. J., J. Shepherd, et al. (1998). "Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: 
a decision analysis." Ann Thorac Surg 66(6): 1876-83; discussion 1883-5. 
21Gambhir, S. S., C. K. Hoh, et al. (1996). "Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in 
the staging and management of non-small-cell lung carcinoma." J Nucl Med 37(9): 1428-36 
22 Verboom, P., H. van Tinteren, et al. (2003). "Cost-effectiveness of FDG-PET in staging non-small cell lung 
cancer: the PLUS study." Eur J Nucl Med Mol Imaging 30(11): 1444-9. 
23 van Tinteren, H., O. S. Hoekstra, et al. (2002). "Effectiveness of positron emission tomography in the 
preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised 
trial." Lancet 359(9315): 1388-93. 
24 Viney, R. C., M. J. Boyer, et al. (2004). "Randomized controlled trial of the role of positron emission 
tomography in the management of stage I and II non-small-cell lung cancer.[see comment]." Journal of Clinical 
Oncology 22(12) 
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all other possible potential strategies to stage lung cancer. However, PET scanning after CT 
positive results is a less clear cut strategy with some studies reporting PET to be cost effective  
and others reporting the opposite to be true. Whilst, studies not taking into account the 
difference between CT negative and CT positive patients may not be picking up this effect.   
Despite the international evidence that PET is likely to be cost effective, especially in 
CT negative patients the results are not entirely transferable to the Australian context, that is, 
excluding the Viney et al trial, which only looked at stage I and II candidates. This is mainly 
because of the different costs structures and reimbursement rates in overseas healthcare 
systems, which makes the translation of them to the Australian context inappropriate. 
 
 
Model Structure  
 
There is great variability in the various national clinical guidelines for treating NSCLC 
and therefore there is some difference in how NSCLC is treated both nationally and even 
locally.
25,26 The model presented here is, therefore, based on a simplification of the potential 
outcomes and pathways that on average most likely to used to treat NSCLC in a cost effective 
manner. The model uses a societal perspective. 
 
As with the HTBS and NICE economic evaluation, the model has been based upon the 
decision pathway used in the Dietlein study. This is considered to be one of the best studies 
conducted on PET. However, there are three main problems with this study and its 
transferability to other decision making contexts has been highlighted.  
First, it does not contain all the plausible alternatives for PET (see the HTBS study for 
other potential strategies).
27 However, this is unlikely to matter greatly as the other strategies 
suggested are unlikely to ever be used in a clinical situation because they deny patients 
histological confirmation of their lung cancer.  
The second problem is that they take a simple approach to combing data from the 
literature on the sensitivity and specificity of tests independently, which is inappropriate. 
Therefore, the sensitivity and specificity for detecting mediastinal metastasis in this study are 
taken from the meta-analysis conducted by the HTBS study and sensitivity for detecting distant 
metastasis is taken from the meta-analysis used in the NICE guidelines.  
The third problem is that the costs are based upon the German reimbursement rates and 
charges and are therefore are inappropriate for translation to other healthcare systems. This has 
bee rectified by inserting comparative costs for tests, surgery and palliative care from 
Australia. Nevertheless, the Dietlein model is still useful for giving the outline of the decision 
problem and some of the parameters are the best estimates available to the model for 
evaluating the cost and benefits of PET in NSCLC.
 The model inputs can be found in table 4.    
 
Strategies  
    
The model takes the two most cost effective strategies that have been identified from 
the literature above. These strategies also offer a histological confirmation of NSCLC and they 
have been applied to both CT positive and CT negative patients. The first strategy is a normal 
CWU without the use of PET. After the NSCLC has been diagnosed patients either proceed to 
                                                 
25 Clinical Practice Guidelines for the Prevention, Diagnosis and Management of Lung Cancer. Australian 
Government; National Health and Research Council. 2004. 
26 National Institute of Health and Clinical Effectiveness, “The Diagnosis and treatment of Lung Cancer; Methods, 
Evidence and Guidance. National Collaboration Centre of Acute Care. 2005. 
27 Bradbury et al. Health Technology Board Scotland, “Positron Emission Tomography (PET) Imaging in Cancer 
Management” October 2002. 
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have a mediastinoscopy or surgery in CT negative patients depending on the results of the 
diagnosis this is based on evidenced cited by Dietlein on a survey of 529 thoracic surgeons. 
The surgeons in the survey believed that in 58% of patients with CT negative results did not 
require any further surgical staging and so went straight to surgery.
 28 This distribution of 
patients going to surgery or mediastinoscopy has therefore been adopted into the model here. 
In CT positive patients, because the likelihood of mediastinal metastasis is high the 
patients proceed to mediastinoscopy for further staging. Following mediastinoscopy patients in 
both CT positive and CT negative will if negative proceed to surgery or if positive they will 
proceed to a course of chemotherapy and radiotherapy in an effort to down stage the cancer. It 
is assumed that patients with distant metastasis are not detected and patients may undergo 
futile surgery or radiotherapy. 
In the second strategy, the patients undergo a CWU but then receive a PET scan to 
improve staging. Therefore, if patients’ results are positive on the FDG-PET then a 
mediastinoscopy will be performed regardless of the lymph node size on CT results. If the 
patients have a negative PET result then they would proceed straight to thoractomy. If PET 
detects distant metastasis then a patients proceed to a course of palliative care.  
 
Underlying Distribution of disease 
 
The baseline population consisted of 62 year old man with whom NSCLC had been 
confirmed and who was fit for surgery or non surgical treatment. Distant metastasis had not 
been detected by conventional staging. The underlying distribution of the disease has been 
taken from the literature.
29
It is assumed that: 
•  30% of patients have N2/3 disease. 
•  10% have occult metastasis 
•  For N0/N1 disease, 23% have enlarged nodes  
•  For N2/3diseas, 60% have enlarged nodes  
 
The underlying distribution of disease for PET candidates in the model given these parameters 
is in table 2 below: 
 
Table 2: HTBS distribution for NSCLC 
  
  N0/1, M0 N0/1, M1  N2/3, M0  N2/3, M1 
Normal lymph nodes  48.4  5.4  10.7  1.2 
Enlarged lymph 
nodes 14.6  1.6  16.3  1.8 
 
  This underlying distribution was questioned in the NICE study, suggesting that the rate 
of distant metastasis was too low at 10% and that the constant rate for both N0/1 and N2/3 
candidates was highly unrealistic. However, given the results of random clinical trials the rate 
of metastasis does not seem too high, especially for N0/N1 patients where both models may be 
                                                 
28 Dietlein, M., K. Weber, et al. (2000). "Cost-effectiveness of FDG-PET for the management of potentially 
operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results." Eur J Nucl 
Med 27(11): p.1600. 
29 Dietlein, M., K. Weber, et al. (2000). & Bradbury et al. Health Technology Board Scotland, “Positron emission 
tomography (PET) imaging in cancer management” October 2002. 
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overestimating the rate of metastasis.
303132 Nevertheless, it is correct to assume based on the 
random clinical trial evidence that the rate of metastasis will not be the same in both N0/1 and 
N2/3 patients. Therefore, I will also test the NICE underlying distribution for lung cancer to 
see if this has any effect on the model this is giveen table 3 below. 
 
 
Table 3: NICE distribution for NSCLC 
 
  N0/1, M0 N0/1, M1  N2/3, M0  N2/3, M1 
Normal lymph nodes  56.98  1.794  3.4  5.82 
Enlarged lymph 
nodes 17.02  6.006  5.1  3.88 
 
Life expectancy and QALYs 
 
  The quality adjusted life year (QALY) is constructed by attaching utility weights to life 
expectancy data with 1 being equivalent to full health and 0 being dead. The possible values 
between full health and death are then ranked on the unpleasantness to be in that health state 
providing the QALY weights.
33 However, it was not possible to find any Australian utility 
values associated with NSCLC. 
Furthermore, there is a lack of data on the utilities of patients with NSCLC overall and 
the data that is used here is not of the highest quality. There is no data on the utilities of 
patients who receive futile operations or radiotherapy, chemotherapy or other supportive care 
for N0/1, N2/3 or M1 diseases.  The model here is based upon the values used in the HTBS 
model; this is because no newer or better estimation of QALYs were found.  
  It has been suggested that patients experience reduced quality of life when they 
undergo surgery in terms of discomfort and anxiety, Therefore it was assumed that undergoing 
surgery results in a lost of quality of life and in this model it has taken the literature value of 
0.15 undergoing surgery. But this is based on estimation and therefore major uncertainty 
surrounds this value.
34 Furthermore, the NICE study suggests that undergoing radical 
radiotherapy should also result in a reduction in quality of life, but to avoid putting any more 
uncertain assumptions into the model it was assumed that undergoing radiotherapy here did not 
result in any loss of quality of life.
 34
 
Table 4. Model Inputs for the model  
 
 
                                                 
30 Herder, G. J., H. Kramer, et al. (2006). "Traditional versus up-front [18F] fluorodeoxyglucose-positron 
emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study." J Clin Oncol 
24(12):  
31 Viney, R. C., M. J. Boyer, et al. (2004). "Randomized controlled trial of the role of positron emission 
tomography in the management of stage I and II non-small-cell lung cancer.[see comment]." Journal of Clinical 
Oncology 22(12):  
32 van Tinteren, H., O. S. Hoekstra, et al. (2002). "Effectiveness of positron emission tomography in the 
preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised 
trial." Lancet 359(9315):  
33 Hunink, M et al, Decision making in Health and Medicine: Integrating evidence and values, Cambrdige, C.U.P, 
2001. p.97. 
34 National Institute of Health and Clinical Effectiveness, “The Diagnosis and treatment of Lung Cancer; Methods, 
Evidence and Guidance. National Collaboration Centre of Acute Care. 2005. Appendices p.272. 
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Variable  Input/ Assumption 
Base Case Patient  62 year old man, NSCLC confirmed and fit 
for surgery or non surgical treatment. 
(Dietlein) 
Diagnostic accuracy    
 
Sensitivity of FDG PET if CT 
negative 
 
86% with 95% CI (0.79, 0.91) - (HTBS) 
Specificity of FDG PET if CT 
negative 
 
90% with 95% CI (0.87, 0.93) - (HTBS) 
Sensitivity of FDG PET if CT 
positive 
 
92% with 95% CI (0.87, 0.95) -  (HTBS) 
Specificity of FDG PET if CT  
positive 
76% with 95% CI (0.69, 0.82) - (HTBS) 
Sensitivity of FDG PET detecting 
distant Metastasis 
93% -  (NICE) 
 
Sensitivity of Mediastinoscopy  72% - (Dietlein) 
Specificity of Mediastinoscopy 
 
100% - (Dietlein) 
Mortality   
CT and PET mortality  0% - (Dietlein) 
   
Surgery mortality 
 
3.7% - (Dietlein) 
Mediastinoscopy mortality 
 




Life expectancy after surgery  N0/1; M0:   4.5 years 
N2/3; M0:   1.8 years 
M1:             0.5 years 
(Dietlein) 
Life expectancy after palliation 
 
N0/1; M0:   2.6 years 
N2/3; M0:  1.8 years 






Percentage of patients straight to 
surgery 
58% (Dietlein) 
Complication rate of surgery 
 
37.5% (Own estimate based on Viney) 
10% (HTBS)  Probability patients upstage during 
thoractomy from N0/1 to N2/3   
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Costs  
All costs were adjusted for inflation and are in 2006 prices and can be seen in the table 
below. It is not currently possible to differentiate FDG-PET scan costs from the National 
Benefit Schedule or the National Hospital Data Collection and so a value was taken from the 
Viney et al article with a value of AUD$2546.6.
35    
 
Table 5: Unit Costs 
 
Diagnostic techniques and treatments  Unit costs 
 
Full body FDG-PET scan 
 
$A 2546.6 – (Viney et al) 
 




EO1B Surgery  
 




$A 2,466 – (Miles) 
 
Course of  Radiotherapy 
 
$A 13,922 –(Rosenthal) 
 
Course of Chemotherapy   $A 9,784 – (See Appendix 2) 
   
 
The surgery costs were taken from the Australian National Hospital Cost Data 
Collection with there being two relevant Diagnostic Related Groups (DRGs). The first is E01A 
which is a major chest procedure with catastrophic clinical complexity (cc) and E01B a major 
chest procedure without catastrophic cc. The distribution of the patients between the two 
procedures was taken from the Viney et al article with approximately 62.5% of patients having 
no catastrophic clinical complexity. The reimbursement rate for E01A was $AUD 21,727 and 
for E01B was $AUD 18,176. This included a comprehensive cost ‘bucket’ for all relevant 
associated costs for these procedures. It was assumed that the mediastinoscopy costs would 
have been factored into the estimation of the DRGs for the chest surgery. Therefore, where a 
mediastinoscopy was not performed the estimated cost of mediastinoscopy which was AUD$ 
2,466 was taken away from the surgery costs.
36
There were no estimates for Australian radiotherapy costs available for treating N2/3 
disease. As a consequence an estimate for the radiotherapy cost of treating SCLC from the 
literature was used. There is evidence that the radiotherapy costs for NSCLC and SCLC overall 
are adequately close.
37 A value of $AUD 13,922 was used for the base case based on 
Rosenthal study of the cost of SCLC for radiotherapy minus diagnosis costs and chemotherapy 
costs.
38  
                                                 
35 Viney, R. C., M. J. Boyer, et al. (2004). "Randomized controlled trial of the role of positron emission 
tomography in the management of stage I and II non-small-cell lung cancer.[see comment]." Journal of Clinical 
Oncology 22(12). 
36 Miles, K. A. (2001). "An approach to demonstrating cost-effectiveness of diagnostic imaging modalities in 
Australia illustrated by positron emission tomography." Australas Radiol 45(1): 9-18. 
37 Fleming, I. Factors influencing hospital cost of lung cancer patients in Northern Ireland.  
38 Rosenthal, M. A., P. J. Webster, et al. (1992). "The cost of treating small cell lung cancer." Med J Aust 156(9): 
605-10. 
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The chemotherapy costs were based on the estimation of the costs used by the HTBS 
for the use of chemotherapy in advanced disease (stage III and IV) NSCLC. The chemotherapy 
cost was estimated for Cisplatin plus Vinorelbine but using Australian data. The cost 
estimation can be seen in Appendix 1.  This took data from the Pharmaceutical Benefit 
Schedule for Cisplatin and Vinorelbine. The inpatient and outpatient costs were taken from the 
literature. A number of assumptions had to be made in calculating the cost with the costs of 
drug preparation and administration, side effects and counselling costs all having to be taken 
from the UK costs estimates and transferred into Australian dollars.
39 To take into account the 
high uncertainty over the chemotherapy and radiotherapy costs a two way sensitivity analysis 
will be undertaken with the values for both costs being doubled and halved. 
If N0/1 M0 patients correctly underwent surgery and survived then they were assumed to be 
free from disease and did not undergo anymore direct costs.  Patients will undergo a course of 
radiotherapy if they are correctly identified as N2/3 M0 patients, and then followed up with a 
course of chemotherapy. It is also assumed that 10% of patients with N2/3 undergoing a futile 
thoractomy will be identified as such and progress to radical radiotherapy and chemotherapy.  
All other patients that undergo a futile thoractomy are assumed to just undergo chemotherapy 
because when the disease reappears it is too late to treat it any other way. Those identified as 
having M1 disease will undergo palliative care in the form of chemotherapy.  
Discounting Costs and Benefits  
 
  The majority of cost occurs immediately after or soon after diagnosis. The only patients 
that are likely to be affected are the N0/1 M0 patients whose life expectancy are 4.5 years if 
successfully operated upon and will receive post operative follow up costs and terminal care 
costs. However, there is no firm data on these costs and any speculation on the make up of 
these costs would be speculative, therefore a decision was made not to discount costs and 
benefits in this model this is consistent with the HTBS and NICE studies.  
                                                 
39 HTBS, “Comment on NICE Technology Appraisal Guidance on the use of Docetaxel and Paclitaxel , 
Gemcitabine and Vinorelbine for the treatment of non small cell lung cancer” 2001B.  




The model was built and run in an EXCEL spreadsheet with 100 patients progressing 
through the model. In the base case result there were 34.3% of patients who were CT positive 
and 65.6% patients who were CT negative. The CT negatives patients comprised of around 48 
patients who were potentially surgically operative and close to 17 who were eligible for non 
surgical treatment. The results of the CT negative patients are given in table 6. 
 
Table 6: CT negative patients  
 
















CWU 48.408  0.1019 
 
13.44 0.361 2.88  20427 
PET 48.486  0.0243 0.239 
 
0.142 2.91  20826 
     
There is a minute difference between the PET and CWU strategies in the number of 
patients that undergo correct operations this includes patients who were correctly staged but 
died as a result of surgery. The small difference is accounted for by the CWU patients having 
to undergo 82% more mediastinoscopies than the PET arm and therefore having a higher risk 
of dying before having a correct operation. This also accounts for the negligible increase in 
number of missed operations with more patients dying in mediastinoscopy in the CWU 
strategy.  
However, the main difference between the two strategies occurs with there being 
around a total of 13.44 more futile surgical operations in the CWU strategy compared to only 
0.24 in the PET strategy. This result can be mostly explained by 58% of the CWU patients 
progressing straight to surgery without undergoing a mediastinoscopy thus accounting for 
around 9.7 of the futile operations.  The other futile thoractomies can be explained by a more 
accurate staging by PET with its high sensitivity and specificity of 0.86 and 0.9 and then 
following positive patients up with a mediastinoscopy this allows better results than just 
conducting a pure mediastinoscopy due to its low sensitivity of 0.72.  Despite the futile 
operations the CWU is still on average cheaper than the PET strategy by around $A400 due to 
the extra cost of PET scanning. The average QALYs between the two strategies are quite close 
with a difference of only 0.026 per patient. The relatively small difference in QALYs and costs 
suggests that the two strategies will be very sensitive to changes in model inputs.  
 
 There were 34.3% of patients who were CT positive with around 14.6 patients who 
were suitable for surgery and 21.6 suitable for non surgical treatment. The baseline results of 
the CT positive patients can be seen in table 7.  
 
Table 7: CT positive patients 
 












CWU  14.41755 0.072  5.93  1.28952  2.09  23578.4 




0.228 2.11  24083.27
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The results for the CT positive patients also show that PET marginally identifies more 
patients correctly for surgery and has a lower number of missed operations; this is again, 
because of CWU patients undergoing more mediastinoscopy with its risk of death than PET 
patients. There are substantial numbers of futile thoractomies occurring in both CWU and PET 
patients with 5.93 and 4.23 respectively. The reason the number of thoractomies is so high is 
because of the low sensitivity of mediastinoscopy at only 72% due to it being unable to reach 
some lymph nodes and with more mediastinal lymph metastasis patients in the section of the 
model this causes an increase in numbers of futile thoractomies proportionally when compared 
to the CT negative patients. The small difference in the number of futile thoractomies between 
the CWU and PET strategies is because of better PET staging. Furthermore, the PET strategy 
also reduces the number of futile radiotherapies that that would occur in the CWU cases due 
PET correctly identifying more of the N2/3 M1 patients. However, there are only small gains 
for improving the correctly staging more radiotherapy patients because N2/3 M0 patients only 
gain around 0.15 QALYs per patient.  The difference in costs and QALYS are even closer 
between the two strategies and suggest that the results will be even more sensitive to changes 
in model inputs and variables.  
 
An ICER examines the additional cost of one strategy compared to another against the 
additional benefits the strategy offers. The ICER is calculated by dividing the differences in 
costs by the difference in patient’s benefit, to give an incremental cost per QALY.
40 The 
incremental costs and QALYs and the resulting ICERS were calculated and presented in table 
8.  
 
Table 8: Totals costs, QALYs and incremental cost effectiveness ratios. 
 




QALYs  ICER 
CT negative 
CWU 1346155.1    189.80     
CT negative PET  1372431.3  26276.2  191.61  1.80  14580.95 
          
CT positive  
CWU 804023.6    71.49     
CT positive PET  821239.3  17215.7  71.82  0.33  52038.52 
          
CWU Arm  2150178.7    261.29     
PET Arm   2193670.6  43491.9  263.43  2.13  20390.81 
 
  
The results show that PET strategy is cost effective compared to just using the CWU 
strategy for both CT negative and CT positive patients with an ICER of $A 14,581 and $A 
52,039 per QALY respectively. The ICER for CT positive patient is expensive and it would be 
down to a decision maker to decide whether this would be an acceptable cost worth paying for 
an additional QALY.   
The difference in results between the CT negative and CT positive results in terms of 
their ICERs is due mostly to PET reducing the number of futile operations in non N0/1 M0 
                                                 
40 Drummond et al Economic evaluation in Health care: Merging theory and practice. (Oxford, O.U.P, 2001) pp. 
11-12. 
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patients. Therefore despite the favourable overall ICER of $A 20,291 between the CWU and 
PET strategy this hides large potential differences between the CT negative and CT positive 
patients.   
 
Testing the Viney et al RCT Trial  
 
 The accuracy of the model was tested by comparing it to the Viney et al randomised 
control trial with the control group (no PET scan) containing 92 patients and a PET group of 91 
patients. In the control arm, 90 of the patients underwent surgery compared with 87 in the PET 
arm. The two arms closely resembled the two strategies that are presented here, although some 
patients did undergo further tests. There were 7 patients who had mediastinoscopy in the PET 
arm and 4 patients that had mediastinoscopy in the control arm. The trial consisted of mainly 
stage I patients who therefore had limited mediastinal lymph node involvement and low rate of 
distant metastasis, thus the majority of the patients in both arms proceeded straight to 
thoractomy explaining the low number of mediastinoscopies carried out in the trial.
41  
The distribution of N0/1 and N2/3 candidates in the trial was inputted into the model 
and the percentage of patients going to mediastinoscopy was changed to represent the 
movements of the actual population in the trial. The model predicted that for the no PET arm 
there would be 82.77 patients having surgery compared to the trial where 90 patients 
underwent a thoractomy. The main reason for the difference was because the rate of metastasis 
in model presented here seems to be too high or at least for those patients with stage I disease. 
The rate of metastasis was then changed to 5% in the model the rate used in other economic 
models such as Dietlein and this gave a result of 87.35 patients proceeding to thoractomy.
42 
The model predicted for the PET arm that there would be 81.86 patients that would receive 
surgery again an underestimation of the 87 patients that did receive surgery in the trial. Once 
again changing the rate of metastasis to 5% provided a result closer to the trial result with 87.1 
patients receiving a surgery. Therefore, it would seem, at least, for stage I NSCLC patients the 
rate of metastasis is too high in the model presented here.  
The HTBS study with its similar model to the one presented here assessed the Van 
Tintertern et al trial, which differed from the Viney trial in that any patients with NSCLC were 
recruited into the model instead of just stage I and II patients. It was found that the HTBS 
model predicted the trial well with their model predicting the difference in futile operations 
between the CWU and PET arms being that PET saved 17 operations per 100 in the model; 
whereas the Dutch trial showed there were actually 16 operations per 100 saved.
4344  
The results of testing the models against the random clinical trails suggest that the 
overall level of metastasis for all patients with NSCLC maybe correct. However, as the NICE 
study suggests, the rate of metastasis may change depending on which stage of NSCLC the 
patients have and with the results here actually suggesting that for stage I candidates the rate of 
distant metastasis maybe too high.
45  
                                                 
41 Viney, R. C., M. J. Boyer, et al. (2004). "Randomized controlled trial of the role of positron emission 
tomography in the management of stage I and II non-small-cell lung cancer.[see comment]." Journal of Clinical 
Oncology 22(12).    
42 Dietlein, M., K. Weber, et al. (2000). "Cost-effectiveness of FDG-PET for the management of potentially 
operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results." Eur J Nucl 
Med 27(11): 1598-609.   
43 Bradbury et al. Health Technology Board Scotland, “Positron emission tomography (PET) imaging in cancer 
management” October 2002. “Economic Evaluation”, pp.23-24. 
44 van Tinteren, H., O. S. Hoekstra, et al. (2002). "Effectiveness of positron emission tomography in the 
preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised 
trial." Lancet 359(9315). 
45 National Institute of Health and Clinical Effectiveness, “The Diagnosis and treatment of Lung Cancer; Methods, 
Evidence and Guidance. National Collaboration Centre of Acute Care. 2005. Appendices p.271.  
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Sensitivity Analysis  
 
There were several assumptions that have had to be made in this model to fill in the 
gaps in our knowledge about the resource use and how the staging of NSCLC is conducted, 
which are based on weak evidence. Therefore sensitivity analyses are used to evaluate how 
changes in assumptions used in economic evaluations change the conclusions of studies.
46 
Therefore to test the robustness of the model and the cost effectiveness of PET several one way 
sensitivity analyses, a two way sensitivity analysis and a probabilistic sensitivity analysis were 
carried out on a number of parameters.  
 
PET accuracy  
 
The first sensitivity analysis that was undertaken was to look at the accuracy of PET 
scanning for staging N2/N3 patients using the confidence intervals from the HTBS meta-
analysis as the upper and lower limits of PET sensitivity and specificity. In the NICE meta-
analysis for the sensitivity and specificity of detecting distant metastasis there were no 
confidence intervals given. Therefore, a value of 6% lower and 4% higher than the point 
estimate was allocated to the PET sensitivity giving a lower limit of 87.4% and upper limit of 
96.7% this is roughly consistent with the confidence intervals around the sensitivity and 
specificity of PET found in the HTBS meta-analysis. See table 10 below. 
 








Change  ICER 
PET Accuracy: lower bound CI for Sensitivity and specificity   
CT negative CWU  1346155.1    189.80     
CT negative PET  1376356.6  30201.5  191.48  1.68  18002.896 
PET Accuracy: Upper bound CI for Sensitivity and specificity   
CT negative CWU  1346155.1    189.80     
CT negative PET  1368637.6  22482.5  191.70  1.90  11841.310 
 
PET Accuracy: lower bound CI for Sensitivity and specificity   
CT positive  
CWU 804023.6    71.49     
CT positive PET  827303.5  23279.9  71.67  0.18  131065.397 
PET Accuracy: Upper bound CI for Sensitivity and specificity     
CT positive  
CWU 804023.6    71.49     
CT positive PET  816788.2  12764.6  71.92  0.43  29730.504 
 
The main direct impact of lowering the sensitivity and specificity is that the number of 
futile operations and missed operations increases in both CT negative patients and CT positive 
patients in the PET strategy. This causes more false negatives in both to be incorrectly sent 
                                                 
46 Drummond et al, Methods for the Economic Evaluation of Health Care Programmes; Third edition. (Oxford, 
O.U.P, 2005), p. 42. 
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straight to surgery and virtually doubled the number of futile surgeries. While the increase in 
the number of false positive patients causes more of the patients to undergo a mediastinoscopy 
with its accompanied risk of death causing some patients to miss out on potentially curable 
surgery. This, therefore, reduces the number of QALYs gained and at the same time increases 
the costs in the PET strategy due to more futile surgeries. The effect of moving from CWU to 
the PET strategy in both CT negative and CT positive patients is a increase in the ICER from 
$A 14,581 to $A18,003 and $A 52,038 to $A 131,065 per QALY.  
 On the other hand, increasing the sensitivity and specificity of PET has the opposite 
outcome of correctly staging more patients reducing the number of futile operations and 
reducing the number of missed operations. This increases the number of QALYs and reduces 
the cost of the treatments with the predictable result of the ICER falling to $A 11,841 in CT 
negative patients and $A 29,730 and CT positive patients. 
The overall effects in the movement of the ICER are smaller when using the higher 
confidence interval because the confidence intervals around the point estimates are not 
symmetrical. The large changes in the CT positive patients ICER can be attributed to the small 
incremental change in the QALYs between the two strategies making the results more 
sensitive. This gives much more uncertainty around the PET strategy in the CT positive 
patients, because it is unlikely from a decision maker’s perspective they will accept an ICER of 
$A 131,065 per QALY if the sensitivity and specificity of PET were found to be lower in 
reality 
 
Surgical morbidity rate 
 
The base case assumed that the surgical morbidity rate caused a reduction in utility of 
0.15 for every operation undergone. This parameter was only an estimation given in the HTBS 
study and so no firm value was attached to it other than what seemed reasonable. The loss of 
utility was therefore decreased to 0.1 and increased to 0.2 to take account of this uncertainty. 
 







Change  QALYS  ICER 
Surgical morbidity decreased to 0.1 
CT negative CWU  1346155.1    192.80    
CT negative PET  1372431.3  26276.2 194.16 1.36  19268.02
Surgical mortality increased to 0.2  
CT negative CWU  1346155.1    186.81    
CT negative PET  1372431.3  26276.2 189.05 2.24  11728.03
 
Surgical morbidity decreased to 0.1 
CT positive  CWU  804023.6    72.50    
CT positive PET  821239.3  17215.7 72.79 0.29  59630.20
Surgical mortality increased to 0.2  
CT positive  CWU  804023.6    70.48    
CT positive PET  821239.3  17215.7 70.85 0.37  46161.57
 
 
The results for decreasing the surgical morbidity to 0.1 shows that for CT negative 
patients the QALYs for both the CWU and PET patients increase. Nevertheless, there are more 
patients who are undergoing surgery whether they are correct operations or futile operations in 
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the CWU patients, therefore there are more patients that benefit from a reduction in surgical 
morbidity than in the PET strategy. Therefore, the ICER of PET over the CWU for CT 
negative patients actually becomes less cost effective with it rising to $A19,268 per QALY.  
This is also the case for the CT positive patients with the number of QALYs increasing 
in both CWU and PET with more surgeries taking place in the CWU patients again and so the 
ICER becomes less cost effective rising to 59,630 per QALY. While the opposite is true when 
the rate of surgical morbidity increases with the ICERs improving to $A11,728 and $A 46,161 
per QALY in both the CT positive and CT negative patients. The sizes of effects are relatively 
tight around the baseline results showing that this is a relatively robust result. 
 
Rate of upstaging during Surgery  
 
The rate of upstaging to radical radiotherapy and chemotherapy in N2/3 M0 patients 
undergoing thoractomy was 10%. This was increased and decreased by 50% to take into the 
consideration the uncertainty of this parameter. 
 







Change  QALYS  ICER 
Increasing upstaging in N2/3 patients during surgery by 50%  
CT negative CWU  1357735.0    189.80     
CT negative PET  1377927.6  20192.6  191.61  1.80  11205.12
Decreasing upstaging in N2/3 patients during surgery by 50% 
CT negative CWU  1340365.2    189.80     
CT negative PET  1369683.1  29318.0  191.61  1.80  16268.86
 
Increasing upstaging in N2/3 patients during surgery by 50%  
CT positive  CWU  810074.6    71.49     
CT positive PET  828543.7  18469.2  71.82  0.33  55827.38 
Decreasing upstaging in N2/3 patients during surgery by 50% 
CT positive  CWU  800998.1    71.49     
CT positive PET  817587.1  16589.0  71.82  0.33  50144.09 
 
 The QALYS were not affected by this change because it is assumed there is no 
difference in terms of quality of life or life expectancy for N2/3 M0 patients undergoing 
chemotherapy or a combination of chemotherapy and radiotherapy in an attempt to downstage 
the cancer. This maybe an incorrect assumption, but there is no evidence to suggest that there 
is indeed a difference and so it was felt rather than add in a further baseless assumption to the 
model the quality of life and life expectancy would be left unchanged.  
However, the costs do increase for both CT negative and CT positive patients as the 
rate of upstaging increase with more N2/3 M0 patients being correctly moved to more 
expensive chemotherapy and radiotherapy. The ICER in CT negative patients becomes more 
cost effective decreasing to $11,205 per QALY and as the rate of upstaging increases due to 
more CWU patients undergo surgery, whether this is correct or futile, relative to the PET 
patients and this incurs greater cost but without any improvement in benefits. When the rate of 
upstaging is decreased this has the opposite effect as fewer patients in the CWU arm undergo 
expensive radiotherapy and chemotherapy with no change to the benefits and so the ICER 
increase to $A 16,269 per QALY.   
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However, unlike the CT negative results we see the ICER for CT positive patients 
increase as the rate of upstaging is increased. This is because slightly more upstaging occurs in 
the PET strategy than the CWU strategy with 0.525 patients being upstaged compared to 0.43 
due to false negatives in PET proceeding straight to surgery without a mediastinoscopy.  
Therefore, we see the PET versus the CWU strategy becoming less cost effective with the 
ICER increasing to $A 55,827 when the rate of upstaging is increased and falling to $A 50,144 
when the rate of upstaging is decreased. These results may radically change if QALY 
assumptions are introduced. 
 
Radiotherapy and chemotherapy costs  
 
  There was much uncertainty about the chemotherapy and radiotherapy costs in the 
model as there is no certain Australia data on costs of these treatments in NSCLC. Therefore, a 
two way sensitivity analyses was carried out to take account of this uncertainty and can be seen 
in table 13 for CT negative patients and    
 
Table 13: Two way sensitivity analysis of the cost of chemotherapy and radiotherapy in 
CT negative patients 
 
  Chemotherapy Costs 
  4000 6000 8000 9,784 10000 12000  14000
6000  696.1 1373.1 2050.1 2653.9 2727.0 3404.0 4081.0
8000  3707.2 4384.2 5061.2 5665.0 5738.1 6415.1 7092.1
10000  6718.3 7395.3 8072.3 8676.1 8749.2 9426.2  10103.2





5 14654.0 15331.0 16008.0
14000  12740.5 13417.5 14094.5 14698.3 14771.4 15448.4 16125.4
16000  15751.6 16428.6 17105.6 17709.4 17782.6 18459.5 19136.5




















20000  21773.8 22450.8 23127.8 23731.6 23804.8 24481.7 25158.7
 
The results show that in the CT negative patients that as the costs of radiotherapy and 
chemotherapy increase the ICERs is also increases. This reflects that PET correctly stages 
more patients with N2/3 for joint chemotherapy and radiotherapy and identifies more patients 
with M1 disease than the CWU strategy. However, the ICERs for the CT negative patients do 
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Table 14: Two way sensitivity analysis of chemotherapy and radiotherapy in CT positive 
patients  
 
  Chemotherapy Costs 
  4000  6000 8000 9784 10000 12000 14000
6000  79436.1  87582.1 95728.1 102994.3 103874.0 112020.0 120166.0
8000  66571.8 74717.7 82863.7 90129.9 91009.7 99155.6  107301.6
10000  53707.4 61853.3 69999.3 77265.5 78145.3 86291.3 94437.2
12000  40843.0 48989.0 57134.9 64401.1 65280.9 73426.9 81572.8
13922  28480.3 36626.3 44772.3 52038.5 52918.2 61064.2 69210.2
14000  27978.6 36124.6 44270.6 51536.8 52416.5 60562.5 68708.5
16000  15114.2 23260.2 31406.2 38672.4 39552.1 47698.1 55844.1




















20000  -10614.4 -2468.5 5677.4 12943.6 13823.4 21969.4 30115.3
 
  
In the CT positive results we see that as the chemotherapy cost increase the ICER starts 
to increase, however when the radiotherapy cost increase the ICER start to fall and eventually 
PET comes to dominates the CWU strategy.  A possible explanation of the difference between 
the results of the CT positive and CT negative patients is the different distribution of the 
underlying disease. The chemotherapy costs raise in both N2/3 and M1 and so the ICER 
increases as chemotherapy costs increase. But, because there are nearly 1.3 more futile 
radiotherapies in the CWU strategy compared to only 0.075 in the PET strategy; we see that at 
low prices for radiotherapy this means that PET is the far more expensive strategy, but as 
radiotherapy costs start to increase then so do the total costs for the CWU strategy reducing the 
difference in costs between the two strategies making PET strategy more cost effective. 
 
Testing the NICE distribution  
 
The NICE paper used a different underlying distribution of lung cancer and, although, 
their distribution improved on some of the assumptions made in previous model it was felt that 
it may have had a rate of metastasis that was too high for N0/1 patients and that overall the 
number of N2/3 patients was too low. Therefore, their distribution was not used as the base 
case. Although it did have the added benefit in suggesting that the rate of metastasis would not 
be the same for both N0/1 and N2/3 patients so it was decided to test the distribution. 




Change  QALYS 
Incremental 
Change  ICER 
NICE distribution of lung cancer patients     
CT negative PET  1361521.06   215.64808    
CT negative CWU  1391567.23 30,046 215.42801 -0.22  DOMINATED
 
NICE distribution of lung cancer patients     
CT positive  PET  598912.2 70.25457    
CT positive CWU  671965.1 73053 73.24 2.98  24484.222
 
 It was found that for CT negative patients the PET strategy dominated the CWU 
strategy this was also what was found in the NICE model with sending all patients to 
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thoractomy being the second best outcome. Turning to look at the CT positive patients, we see 
that the CWU strategy was actually more cost effective than the PET strategy with an ICER of 
$A 24,484 per QALY. It is not possible to compare this with the NICE results because they did 
not look at the CT positive patients as they believed this would not be a cost effective outcome 
for PET as the model here shows.  
 
Probabilistic sensitivity analysis 
 
  The role of probabilistic modelling is to further reflect the uncertainty in the parameters 
used in the decision model and to see what effect this has, in this case, over the incremental net 
benefit.
47 The parameters in the model were given distributions with probabilities and utilities 
given a beta distribution and all other costs and life expectancy given a gamma distribution. A 
simulation was then run 10,000 times using the macro given in appendix 4.  
  The graph below shows the following distribution of QALYS and costs and their 
subsequent ICERs from the 10,000 simulation runs for the CT negative patients. It is clear that 
the distribution is primary located in the more costly and more effective section of the graph 
with a tight distribution of point with few extreme values. The current willingness to pay for 
one QALY is not known and so the existing threshold ratio has not been added, but it clearly 






































The next graph shows the distribution of ICERs in the 10,000 simulation runs for CT 
positive patients. The distribution is also mostly located in the more effective and more costly 
quadrant of the cost effectiveness plane. However the majority QALYs are located in a narrow 
                                                 
47 Briggs A., Claxton K. and Sculpher MJ. Decision analytic modelling for the evaluation of health technologies. 
O.U.P., Oxford, 2006. p77 
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band of QALY scores mostly ranging from 0 to 0.9 QALYS compared to the CT negative 
range of around 0.5 to 3 QALYs, whilst there is similar variability in the costs to the CT 
negative results. This results in the clear implication that higher threshold ratio will be needed 
for the PET strategy to be implemented by a decision maker than compared to the CT negative 
results. There are also a larger number of negative QALYs in the CT positive with a 
significantly dense spread to the left of the graph suggesting much more uncertainty in the CT 
positive results. 
 







































  The mean, median and inter quartile range were taken from the simulation of 10,000 
runs.  In the CT negative patients the mean ICER for the PSA is very close to the mean in the 
baseline result with only a difference of about $A 37 per QALY and therefore shows that the 
baseline model is robust in the results with little variability in the parameters. The median is 
also close to the mean and shows that the distribution does not appear to be heavily skewed.  
 









QALYS  ICER 
        
Mean  26197.16  1.80 14543.1 
Median   25628.17  1.76  13596.0 
Inter-
Quartiles 25  10692.55  1.23  5047.8 
 75  43202.51  2.38  25236.8 
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The CT positive patients show that the mean is also very close to the mean in the 
original baseline result but not as close as the CT negative results with the a difference of 
around $A 816 per QALY cheaper than the PSA result. But the most interesting result is that 
the median is so low compared to the median suggesting that there is a substantial amount of 
skewness in the results and this could be potentially suggesting that the is a lot of variability in 
outcomes and is further evidence to question  PET as a cost effective strategy in CT positive 
patients.  
 









QALYs  ICER 
        
Mean  16742.87  0.33 50854.9 
Median   15499.46  0.40  27256.2 
Inter- 
Quartiles 25  5813.80  0.20  64.8 
 75  26654.65  0.56  62985.8 
 
 
  We now turn to look at the cost effectiveness acceptability curve (CEAC) for PET and 
CWU in NSCLC for CT negative patients. A CEAC shows the probability that an intervention 
is more cost effective than it comparator. The results for CT negative patients show that as the 
threshold willingness-to-pay increases the probability that PET is cost effective rises while the 
probability that CWU is cost effective decreases.
 48 The CEAC shows the decision maker the 
probability that they have made the right on wrong decision and, in this case, the decision 
maker will make the right decision more than 50% of the time if the willingness to pay is just 
over $A 15,000, while if the decision maker is willing to pay $A 50,000 the probability that 
they have made the right decision increases to 90%.
49
 
                                                 
48 Drummond et al, Methods for the Economic Evaluation of Health Care Programmes; Third edition. (Oxford, 
O.U.P, 2005), p. 265. 
49 Drummond et al, Methods for the Economic Evaluation of Health Care Programmes; Third edition. (Oxford, 
O.U.P, 2005), p. 267 
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The results for the CEAC in CT positive are shown in graph 4 below. The threshold 
needed for the probability that PET is 50% more of the time cost effective compared to the 
CWU strategy would be $A 43,000. However, given the sensitivity of the CT positive strategy 
results to changes in individual parameters much more certainty would be needed before it 
would be acceptable to recommend PET in CT positive patients as robustly cost effective 
result. 
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Discussion  
 
The two most cost effective strategies, which also allowed histological confirmation of 
the NSCLC, were identified from the literature. The study here suggests that PET is the more 
cost effective than the CWU for both the CT negative and CT positive patients with ICERs of 
$A 14,580 per QALY and $A 52,039 per QALY respectively. The CT positive ICER is high, 
but there is no explicit threshold used in the Australian health care system for an acceptable 
ICER, although, it is generally implicitly assumed to be around $A 50,000 dollars per QALY. 
So whether this strategy would be used by a societal decision maker is questionable. However, 
due to the large amount of variability in the strategy’s ICERs shown by the sensitivity analyses 
this throws the strategy’s cost effectiveness seriously into doubt.   
   However, the sensitivity analyses show that for CT negative patients the results seem to 
be extremely robust. The only sensitivity analysis that saw the ICER decrease noticeably was 
when the rate of metastasis was decreased to 0.05 and then the ICER increased to $A 54,453 
per QALY, otherwise it stayed within a range of $A 11,728 to $A 19,268 or it dominated the 
CWU strategy.  
  This study largely confirms the results of the previous studies but in an Australian 
context which has not been looked at before and it is thought that this is the first time that a 
probabilistic sensitivity analysis has been carried out on PET looking at CT positive and CT 
negative patients separately. Compared to the other studies there was more movement in the 
results when the individual parameters were changed especially for the CT positive patients. 
This no doubt reflects the substantial uncertainty over some of parameters in the model 
especially concerning the underlying distribution of disease. This study has provided more 
evidence suggesting that rate of metastasis is not the same for patients with different stages of 
NSCLC. Further work on the quality of life estimates and the cost of radiotherapy and 
chemotherapy in an Australian context would yield extra certainty in the reliability of these 
results. 
 Despite the overwhelming international evidence and the now this study showing that 
PET in CT negative patients is a cost effective and with greater uncertainty for CT positive 
patients these results should still be interpreted cautiously due to many of the assumptions used 
in the modelling. However, the recent introduction of a new generation of PET scanners and 
the new combination CT-PET scanners that not only ensure better T staging, but improvements 
in N and M staging. We should, therefore,  start to see the cost effectiveness of PET improve 
even further as scanning times are reduced and the accuracy improves .
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50 Devaraj, A., G. J. Cook, et al. (2007). "PET/CT in non-small cell lung cancer staging-promises and problems." 
Clinical Radiology 62(2): p.106 
 






Appendix 1 Estimating the cost of Chemotherapy  
 
Estimation of the Cost of Chemotherapy for a course of  Cisplatin - Vinobrine  to 
treat NSCLC 
  
Cost per cycle   
Cisplatin  3 x $A 61.05 (PBS) 
In patient attendances  1 x $A 650 (Rosenthal) 
Out Patient attendances  3x A$ 303.8 Rosenthal 
  
Cost Per Course   
Number of Cycles  3 
Vinolbrine  $A 3601.44 (PBS) 
Drug preparation  $A 24.2 (Estimation based on HTBS) 
Side Effects  $A 1,100 (Estimation based on HTBS) 
  
Cost per cycle  $A 1,744.6 
Cost per course  $A 9,784.0 
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Appendix 3: Summary of the studies found in the literature review 
 
 















a) Patients go straight to 
thoracotomy  
b) Patients have a 
mediastinoscopy and then 
receive either radical 
radiotherapy (N2/N3) or 
Thoractomy (N0/1) 
c) Patients have a PET 
scan and then receive 
either active supportive 
care (M1+) OR 
Thoractomy (M0,N0/N1) 
OR Radical radiotherapy 











for surgery  
 
Cost Utility   Quality adjusted 












c) vs a) 
£7,199/QALY 
gained 










a) Patients go straight to 
radical radiotherapy  
b) Patients have a PET 
scan and then receive 
either ASC (M1) or 
thoractomy     (N0/1) or  









Cost Utility  Quality adjusted 
life year (QALYs) 
Decision 
Analysis 
b) vs a ) 4.3 
QALYs 
b) vs a) 
40,936 
b) vs a) 
£9,489/QALY 
gained 
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HTBS Bradbury 
et al, (2002), 
Scotland 
a) All to surgery  
b) Palliatation 
c) Mediastinoscopy 
d) Mediastinoscopy with 
PET after a negative 
mediastinoscopy. 
e) PET 






Cost Utility  Quality adjusted 
life year (QALYs)  
Decision 
Analysis 
a) 2.88 QALYS 
b) 1.46 QALYS 
c) 2.89 QALYS 
d) 2.76 QALYS 
e) 2.77 QALYS 
f) 2.76 QALYS 







g) 4, 854 
 
c) vs a) 
£18,589/QALY 
gained  
g) vs c) 
£10,475/QALY 
gained 
b, d, e and f were 
all dominated by 
g.  
Dietlein et al 
2000. Germany 
a) Conventional staging – 
CT and Mediastinoscopy  
 
b) Whole body FDG-PET 
in patients with negative 
CT 
 
c) Whole body FDG-PET 
in all patients – if positive 
PET then Mediastinoscopy  
 
d) Whole body  FDG-PET 
in all patients – excluded 
form surgery if positive 
PET and Positive CT 
 
Whole body FDG-PET in 
all patients – excluded 













a) 3.30 LYs 
 
b) 3.32 LYs 
 
c) 3.33 LYs  
 
d) 3.39 LYs 
 
e) 3.36 LYs 
 






d) 16, 279 
 
e) 15, 839  
b) vs a) €143/LY 
gained  
 
c) vs b) €36,6670/ 
LY gained. 
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Hayashi et al 
(2005) Japan 
a) CT only  (If negative 
surgery, If positive 
chemotheraphy) 
 
b) PET +CT ( If negative 
thoractomy, if positive 
chemotheraphy) 
 
c) PET + CT (If PET 
positive then  
mediastinoscopy, if 




free of M1 
Cost utility   Quality adjusted 
Life Year  (QALY)  
Decision 
Analysis  
a) 4.79 LYs/ 
4.35 QALYs 
 
b) 5.33 LYs/ 
4.93 QALYs 
 
c) 5.68 LYs/  
5.33 QALYS 
 
n/a c)  vs  a) 
$4,775/QALY 
 




Nguyen et al 
(2005) Canada  
a) CT (If positive then 
mediastinoscopy, if 
negative then surgery) 
 
b) CT + PET (Biopsy or 
mediastinoscopy to 






LY gained  Decision 
Analysis 
b) vs a) 0.27 
LY 
b) vs a) 
$1,268 




a) CT –  if positive then 
Mediastinoscopy  
 
b) CT and PET – if 
positive PET or positive 
CT then mediastinoscopy 
 








LY gained  Decision 
analysis 
b) vs a) +3 days  b) vs a) -
$1,154 
c) vs a) -
$2267 




  33  
  34 











a) CT – if positive then 
mediastinoscopy 
 
b) PET after negative CT 
(mediastinoscopy after +ve 
PET or +ve CT ) 
 
c) PET and CT 
(mediastinoscopy after +ve 
PET) 
 
d) PET and CT 
(mediastinoscopy after +ve 






LY gained  Decision 
Analysis 
b) vs a) 0.007 
LY  
c) vs a) 0.009 
LY 
d) vs a) 0.007 
LY 
b) vs a) $177 
c) vs a) $638 
d) vs a) $965 
b) vs a) $25,286/ 
LY gained 
c) vs a) $70,889/ 
LY gained  
d) vs a) $37,857/ 
LY gained 
Verboom et al 
(2003) 
The Netherlands  
 
a) Conventional work up 
(CWU)  Including CT, 
MRI, ultrasound, bone 
scan, invasive test 
brochoscopym 
mediastinoscopy and 
invasive surgery.  
 












a) 39 futile 
thoractomies 
 
b) 19 futile 
thoractomies  
a) € 9,573 
 
b) € 8284  
CWU + PET 
dominates  
Viney et al  
(2002) Australia 
a) CT scan (Thorax, upper 
abdomen and brain + X 
ray)  
 
b) CT scan +  PET   
Patients 
with stage I 











b) vs a) 0.22 
thoractomies 
avoided  
b vs a) $A 
2,655 
b) vs a) $120,681/ 
thoractomy 
avoided 
Kosuda et al 
(2002) 
a) Whole body (WB) PET  







Life expectancy  Decision 
analysis 
b) vs a) gain in 
LE of minus 
0.0246 years  to 
0.0136 years.  
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